E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« Braintree Laboratories, Inc. v. Breckenridge Pharmaceutical, Inc. (Fed. Cir. 2017) | Main | Guest Post: Regnoicorp -- A Miscarriage of Justice Calling for En Banc Reconsideration »

May 09, 2017

Comments

Two thoughts:

(1) Wait, Par has a *registered trademark* on "Adrenalin" for a composition containing epinephrine? How is that not generic?

(2) Please correct me if I am wrong about this, but it was my understanding that once one the ANDA applicant files the application with the paragraph IV box checked, that starts the clock ticking to file the infringement suit. Does the clock reset every time the paragraph IV applicant later changes the formulation?

The comments to this entry are closed.

November 2017

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30